Cancer Molecular Pathology, School of Medicine, Griffith University, Gold Coast, Queensland 4222, Australia; Department of Anatomy, Faculty of Medicine, University of Peradeniya, Sri Lanka.
Cancer Molecular Pathology, School of Medicine, Griffith University, Gold Coast, Queensland 4222, Australia.
Exp Mol Pathol. 2021 Jun;120:104642. doi: 10.1016/j.yexmp.2021.104642. Epub 2021 Apr 24.
Heme is a crucial compound for cell survival but is also equipped with the potential to be toxic and carcinogenic to cells. However, with the recent advancement of knowledge regarding ferroptosis, the iron mediated cell death, heme can be postulated to induce tumour suppression through ferroptosis. This review summarizes the literature on the carcinogenic and anticarcinogenic properties of heme with specific emphasis on the alterations observed on heme synthesis, metabolism and transport in tumour cells.
Literature search was performed in PubMed data base using the MeSH terms 'heme iron or heme', 'cancer or carcinogenesis' and 'tumour suppression' or 'anticarcinogenic properties. Out of 189 results, 166 were relevant to the current review.
Heme supports carcinogenesis via modulation of immune cell function, promoting inflammation and gut dysbiosis, impeding tumour suppressive potential of P53 gene, promoting cellular cytotoxicity and reactive oxygen species generation and modulating Nfr2 /HO-1 axis. The carcinogenic and anticarcinogenic properties of heme are both dose and oxygen concentration dependant. At low doses, heme is harmless and even helpful in maintaining the much-needed redox balance within the cell. However, when heme exceeds physiological concentrations, it could initiate and propagate carcinogenesis, due to its ability to produce reactive oxygen species (ROS). The same phenomenon of heme mediated ROS generation could be manipulated to initiate tumour suppression via ferroptosis, but the therapeutic doses are yet to be determined.
Heme iron possesses powerful carcinogenic and anticarcinogenic properties which are dosage and oxygen availability dependant.
血红素是细胞生存所必需的关键化合物,但也具有潜在的毒性和致癌性。然而,随着铁死亡(一种由铁介导的细胞死亡)相关知识的最新进展,血红素可以通过铁死亡诱导肿瘤抑制。本综述总结了血红素的致癌和抗癌特性的文献,特别强调了肿瘤细胞中血红素合成、代谢和转运的变化。
在 PubMed 数据库中使用 MeSH 术语“血红素铁或血红素”、“癌症或致癌作用”和“肿瘤抑制”或“抗癌特性”进行文献检索。在 189 个结果中,有 166 个与当前综述相关。
血红素通过调节免疫细胞功能、促进炎症和肠道菌群失调、阻碍 P53 基因的肿瘤抑制潜力、促进细胞毒性和活性氧(ROS)生成以及调节 Nfr2/HO-1 轴来支持致癌作用。血红素的致癌和抗癌特性都依赖于剂量和氧浓度。在低剂量下,血红素是无害的,甚至有助于维持细胞内急需的氧化还原平衡。然而,当血红素超过生理浓度时,由于其产生活性氧(ROS)的能力,它可能会引发并促进致癌作用。血红素介导的 ROS 生成的这种现象可以通过铁死亡来操纵以启动肿瘤抑制,但治疗剂量尚待确定。
血红素铁具有强大的致癌和抗癌特性,这取决于剂量和氧的可用性。